Merck & Co has ended development of preladenant, an experimental drug for Parkinson's disease, after initial data from three late-stage trials proved disappointing.New Jersey-based Merck said the decision to discontinue the studies was not based on any safety findings.
"Parkinson's disease is very complex, making it difficult to treat patients and develop novel therapeutic approaches," David Michelson, vice president, clinical research, Neuroscience and Ophthalmology at Merck Research Laboratories, said in a statement.
Really? What disease is less complex???
No comments:
Post a Comment